Could pregnancy be the perfect time to screen for cancer genes?

NCT ID NCT07195071

Recruiting now Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether offering hereditary cancer screening alongside standard prenatal genetic tests is practical and acceptable. About 1000 pregnant or preconception patients will be offered both tests. The goal is to see how many complete the cancer screening and how they feel about it afterward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Natera Empower Comprehensive Hereditary Cancer Panel (blood test)
What this could lead to: If successful, this could show that pregnancy is a good time to screen for inherited cancer risk, potentially leading to earlier detection and prevention.
What could go wrong: This is a small feasibility study (1000 people) that only measures interest and regret, not cancer outcomes. It may not change practice or benefit participants directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY CANCER SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary neoplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY CANCER SYNDROME

Contacts and locations

Locations

Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.